[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100494800":3},{"organization":4,"armGroups":7,"interventions":44,"overallOfficials":89,"centralContacts":94,"locations":101,"responsibleParty":472,"collaborators":474,"id":486,"slug":487,"hasResults":488,"nctId":489,"briefTitle":490,"officialTitle":491,"acronym":492,"eligibilityCriteria":493,"healthyVolunteers":488,"sex":494,"minAge":99,"maxAge":99,"enrollmentInfo":495,"targetDuration":99,"studyType":498,"phases":499,"briefSummary":502,"conditions":503,"keywords":506,"overallStatus":104,"whyStopped":99,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":541,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":548,"locationsCount":549},{"fullName":5,"class":6},"Cancer Research UK","OTHER",[8,14,19,24,29,34,39],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment Arm 1: Alectinib","EXPERIMENTAL","This alectinib treatment arm is for adult, paediatric and TYA patients with ALK-positive cancers.",[13],"Drug: Alectinib",{"label":15,"type":10,"description":16,"interventionNames":17},"Treatment Arm 2: Atezolizumab","This atezolizumab treatment arm is for adult, paediatric and TYA patients with cancers with high tumour mutational burden (TMB) or microsatellite instability high (MSI-high) or proven (previously diagnosed) constitutional mismatch repair deficiency (CMMRD).",[18],"Drug: Atezolizumab",{"label":20,"type":10,"description":21,"interventionNames":22},"Treatment Arm 3: Entrectinib","This entrectinib treatment arm is for adult, paediatric and TYA patients with ROS1 gene fusion-positive cancers.",[23],"Drug: Entrectinib",{"label":25,"type":10,"description":26,"interventionNames":27},"Treatment Arm 4: Trastuzumab in combination with pertuzumab","This trastuzumab and pertuzumab treatment arm is for adult, paediatric and TYA patients with cancers with HER2 amplification or activating mutations.",[28],"Drug: Trastuzumab in combination with pertuzumab",{"label":30,"type":10,"description":31,"interventionNames":32},"Treatment Arm 5: Vemurafenib in combination with cobimetinib","This vemurafenib and cobimetinib treatment arm is for BRAF V600 mutation-positive cancers occurring in adults only.",[33],"Drug: Vemurafenib in combination with cobimetinib",{"label":35,"type":10,"description":36,"interventionNames":37},"Treatment Arm 6: Capmatinib","This capmatinib treatment arm is for adult patients with cancers harbouring MET dysregulations.",[38],"Drug: Capmatinib",{"label":40,"type":10,"description":41,"interventionNames":42},"Treatment Arm 7: Dabrafenib in combination with trametinib","This dabrafenib and trametinib treatment arm is for adult, paediatric and TYA patients with cancers harbouring BRAF V600 mutations.",[43],"Drug: Dabrafenib in combination with trametinib",[45,52,58,64,70,76,82],{"type":46,"name":47,"description":48,"armGroupLabels":49,"otherNames":50},"DRUG","Alectinib","Adult patients will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.\n\nPaediatric patients with a body weight ≥40 kg and who are able to swallow the capsules will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.\n\nEach cycle of treatment will consist of 28 days and patients may continue on treatment until disease progression without clinical benefit, unacceptable AEs or withdrawal of consent.",[9],[51],"Alecensa",{"type":46,"name":53,"description":54,"armGroupLabels":55,"otherNames":56},"Atezolizumab","Adult patients will receive 1200 mg of atezolizumab intravenously every 21 days.\n\nPaediatric patients will receive atezolizumab at a dose of 15 mg\u002Fkg (maximum 1200 mg) every 21 days.\n\nPatients may continue on treatment until disease progression without clinical benefit, unacceptable AEs or withdrawal of consent.",[15],[57],"Tecentriq",{"type":46,"name":59,"description":60,"armGroupLabels":61,"otherNames":62},"Entrectinib","Adult and paediatric patients with body surface area (BSA) ≥1.51 m\\^2 will receive entrectinib orally at a dose of 600 mg daily dose (three 200 mg capsules per day).\n\nPaediatric patients with BSA \\\u003C1.51 m\\^2 will receive a dose adjusted for BSA. Each cycle of treatment will consist of 28 days and patients may continue until disease progression without clinical benefit, unacceptable AEs or withdrawal of consent.",[20],[63],"Rozlytrek",{"type":46,"name":65,"description":66,"armGroupLabels":67,"otherNames":68},"Trastuzumab in combination with pertuzumab","The initial loading dose of trastuzumab is 8 mg\u002Fkg body weight followed thereafter by a maintenance dose of 6 mg\u002Fkg body weight administered intravenously every 21 days.\n\nThe initial loading dose of pertuzumab is 840 mg followed thereafter by a maintenance dose of 420 mg administered intravenously every 21 days. Paediatric patients will receive a dose of pertuzumab adjusted by body weight.\n\nPatients may continue until disease progression without clinical benefit, unacceptable AEs or withdrawal of consent.",[25],[69],"Herceptin in combination with Perjeta",{"type":46,"name":71,"description":72,"armGroupLabels":73,"otherNames":74},"Vemurafenib in combination with cobimetinib","Patients will receive vemurafenib at a dose of 960 mg (four tablets of 240 mg) orally on a twice daily schedule throughout a 28-day cycle.\n\nPatients will receive cobimetinib at a dose of 60 mg (three tablets of 20 mg) to be taken orally, once daily for 21 consecutive days (days 1 to 21 in each 28-day cycle); followed by a 7-day break.\n\nPatients may continue on treatment until disease progression without clinical benefit, unacceptable AEs or withdrawal of consent.",[30],[75],"Zelboraf in combination with Cotellic",{"type":46,"name":77,"description":78,"armGroupLabels":79,"otherNames":80},"Capmatinib","Patients will receive capmatinib orally at a daily dose of 800 mg consisting of 400 mg (two 200 mg tablets) twice daily. Each cycle of treatment will consist of 28 days and patients may continue on treatment until disease progression without clinical benefit, unacceptable AEs or withdrawal of consent.",[35],[81],"Tabrecta",{"type":46,"name":83,"description":84,"armGroupLabels":85,"otherNames":86},"Dabrafenib in combination with trametinib","Adult patients (≥18 years) will receive dabrafenib at a dose of 150 mg (two 75 mg tablets) twice daily (total daily dose 300 mg). Paediatric patients (1 to \\\u003C12 years) will receive dabrafenib dose adjusted by body weight as 10 mg dispersible tablets orally twice daily. Paediatric patients (≥12 years) and TYA patients (16 to \\\u003C18 years) will have the option to receive adult or paediatric dosing. Adult patients will receive trametinib at a daily dose of 2 mg (one 2 mg tablet) orally once daily (total daily dose 2 mg). Paediatric patients receive trametinib at a dose adjusted by body weight as 0.05 mg\u002Fm\\^2 powder for oral solution twice daily. Paediatric patients (≥12 years) and TYA patients (16 to \\\u003C18 years) will have the option to receive adult or paediatric dosing. Each cycle of treatment will consist of 28 days. Patients may continue until disease progression without clinical benefit, unacceptable AEs or withdrawal of consent.",[40],[87,88],"Tafinlar in combination with Mekinist","Finlee in combination with Spexotras",[90],{"name":91,"affiliation":92,"role":93},"Matthew Krebs, Dr","The Christie Hospital","PRINCIPAL_INVESTIGATOR",[95],{"name":96,"role":97,"phone":98,"phoneExt":99,"email":100},"Aida Sarmiento Castro","CONTACT","+44 207 242 0200",null,"determine@cancer.org.uk",[102,120,135,148,163,172,187,203,215,228,243,255,270,285,300,313,325,340,351,366,381,391,406,415,430,442,457],{"facility":103,"status":104,"city":105,"state":99,"zip":106,"country":107,"countryCode":108,"cosmosGeoPoint":109,"geoPoint":114,"contacts":115},"Belfast City Hospital","RECRUITING","Belfast","BT9 7AB","United Kingdom","UK",{"type":110,"coordinates":111},"Point",[112,113],-5.92541,54.59682,{"lat":113,"lon":112},[116,119],{"name":117,"role":97,"phone":99,"phoneExt":99,"email":118},"Vicky Coyle, Prof","V.Coyle@qub.ac.uk",{"name":117,"role":93,"phone":99,"phoneExt":99,"email":99},{"facility":121,"status":104,"city":122,"state":99,"zip":123,"country":107,"countryCode":108,"cosmosGeoPoint":124,"geoPoint":128,"contacts":129},"University Hospital Birmingham","Birmingham","B15 2TT",{"type":110,"coordinates":125},[126,127],-1.89983,52.48142,{"lat":127,"lon":126},[130,134],{"name":131,"role":97,"phone":132,"phoneExt":99,"email":133},"Gary Middleton, Prof","0121 371 3573","G.Middleton@bham.ac.uk",{"name":131,"role":93,"phone":99,"phoneExt":99,"email":99},{"facility":136,"status":137,"city":122,"state":99,"zip":138,"country":107,"countryCode":108,"cosmosGeoPoint":139,"geoPoint":141,"contacts":142},"Birmingham Children's Hospital","NOT_YET_RECRUITING","B4 6NH",{"type":110,"coordinates":140},[126,127],{"lat":127,"lon":126},[143,147],{"name":144,"role":97,"phone":145,"phoneExt":99,"email":146},"Gerard Millen, Dr","07921843607","g.millen@nhs.net",{"name":144,"role":93,"phone":99,"phoneExt":99,"email":99},{"facility":149,"status":104,"city":150,"state":99,"zip":151,"country":107,"countryCode":108,"cosmosGeoPoint":152,"geoPoint":156,"contacts":157},"Bristol Royal Hospital for Children","Bristol","BS2 8BJ",{"type":110,"coordinates":153},[154,155],-2.59665,51.45523,{"lat":155,"lon":154},[158,162],{"name":159,"role":97,"phone":160,"phoneExt":99,"email":161},"Antony Ng, Dr","0117 342 8044","Antony.Ng@uhbw.nhs.uk",{"name":159,"role":93,"phone":99,"phoneExt":99,"email":99},{"facility":164,"status":104,"city":150,"state":99,"zip":165,"country":107,"countryCode":108,"cosmosGeoPoint":166,"geoPoint":168,"contacts":169},"Bristol Haematology and Oncology Centre","BS2 8ED",{"type":110,"coordinates":167},[154,155],{"lat":155,"lon":154},[170,171],{"name":159,"role":97,"phone":160,"phoneExt":99,"email":161},{"name":159,"role":93,"phone":99,"phoneExt":99,"email":99},{"facility":173,"status":104,"city":174,"state":99,"zip":175,"country":107,"countryCode":108,"cosmosGeoPoint":176,"geoPoint":180,"contacts":181},"Addenbrooke's Hospital","Cambridge","CB2 OQQ",{"type":110,"coordinates":177},[178,179],0.11667,52.2,{"lat":179,"lon":178},[182,186],{"name":183,"role":97,"phone":184,"phoneExt":99,"email":185},"Bristi Basu, Dr","01223 596105","bb313@medschl.cam.ac.uk",{"name":183,"role":93,"phone":99,"phoneExt":99,"email":99},{"facility":188,"status":104,"city":189,"state":99,"zip":190,"country":107,"countryCode":108,"cosmosGeoPoint":191,"geoPoint":195,"contacts":196},"Velindre Cancer Centre","Cardiff","CF14 2TL",{"type":110,"coordinates":192},[193,194],-3.18,51.48,{"lat":194,"lon":193},[197,202],{"name":198,"role":97,"phone":199,"phoneExt":200,"email":201},"Robert Jones, Dr","02920 615888","6327","Robert.Hugh.Jones@wales.nhs.uk",{"name":198,"role":93,"phone":99,"phoneExt":99,"email":99},{"facility":204,"status":104,"city":189,"state":99,"zip":205,"country":107,"countryCode":108,"cosmosGeoPoint":206,"geoPoint":208,"contacts":209},"Cardiff Children's Hospital","CF14 4XW",{"type":110,"coordinates":207},[193,194],{"lat":194,"lon":193},[210,214],{"name":211,"role":97,"phone":212,"phoneExt":99,"email":213},"Madeline Adams, Dr","02921842285","madeline.adams@wales.nhs.uk",{"name":211,"role":93,"phone":99,"phoneExt":99,"email":99},{"facility":216,"status":104,"city":217,"state":99,"zip":218,"country":107,"countryCode":108,"cosmosGeoPoint":219,"geoPoint":223,"contacts":224},"Western General Hospital","Edinburgh","EH4 2XU",{"type":110,"coordinates":220},[221,222],-3.19648,55.95206,{"lat":222,"lon":221},[225,227],{"name":226,"role":97,"phone":99,"phoneExt":99,"email":99},"Stefan Symeonides, Dr",{"name":226,"role":93,"phone":99,"phoneExt":99,"email":99},{"facility":229,"status":104,"city":230,"state":99,"zip":231,"country":107,"countryCode":108,"cosmosGeoPoint":232,"geoPoint":236,"contacts":237},"The Beatson Hospital","Glasgow","G12 OYN",{"type":110,"coordinates":233},[234,235],-4.25763,55.86515,{"lat":235,"lon":234},[238,242],{"name":239,"role":97,"phone":240,"phoneExt":99,"email":241},"Patricia Roxburgh, Dr","0141 301 7118","Patricia.Roxburgh@glasgow.ac.uk",{"name":239,"role":93,"phone":99,"phoneExt":99,"email":99},{"facility":244,"status":104,"city":230,"state":99,"zip":245,"country":107,"countryCode":108,"cosmosGeoPoint":246,"geoPoint":248,"contacts":249},"Royal Hospital for Children Glasgow","G51 4TF",{"type":110,"coordinates":247},[234,235],{"lat":235,"lon":234},[250,254],{"name":251,"role":97,"phone":252,"phoneExt":99,"email":253},"Milind Ronghe, Dr","0141 452 6692","Milind.Ronghe@ggc.scot.nhs.uk",{"name":251,"role":93,"phone":99,"phoneExt":99,"email":99},{"facility":256,"status":104,"city":257,"state":99,"zip":258,"country":107,"countryCode":108,"cosmosGeoPoint":259,"geoPoint":263,"contacts":264},"Leicester Royal Infirmary","Leicester","LE1 5WW",{"type":110,"coordinates":260},[261,262],-1.13169,52.6386,{"lat":262,"lon":261},[265,269],{"name":266,"role":97,"phone":267,"phoneExt":99,"email":268},"Harriet Walter, Dr","01162587602","harriet.walter1@nhs.net",{"name":266,"role":93,"phone":99,"phoneExt":99,"email":99},{"facility":271,"status":104,"city":272,"state":99,"zip":273,"country":107,"countryCode":108,"cosmosGeoPoint":274,"geoPoint":278,"contacts":279},"Alder Hey Hospital","Liverpool","L14 5AB",{"type":110,"coordinates":275},[276,277],-2.97794,53.41058,{"lat":277,"lon":276},[280,284],{"name":281,"role":97,"phone":282,"phoneExt":99,"email":283},"Lisa Howell, Dr","0151 293 3679","Lisa.Howell@alderhey.nhs.uk",{"name":281,"role":93,"phone":99,"phoneExt":99,"email":99},{"facility":286,"status":104,"city":287,"state":99,"zip":288,"country":107,"countryCode":108,"cosmosGeoPoint":289,"geoPoint":293,"contacts":294},"University College London Hospital","London","NW1 2BU",{"type":110,"coordinates":290},[291,292],-0.12574,51.50853,{"lat":292,"lon":291},[295,299],{"name":296,"role":97,"phone":297,"phoneExt":99,"email":298},"Martin Forster, Prof","020 3447 5085","M.Forster@ucl.ac.uk",{"name":296,"role":93,"phone":99,"phoneExt":99,"email":99},{"facility":301,"status":104,"city":287,"state":99,"zip":302,"country":107,"countryCode":108,"cosmosGeoPoint":303,"geoPoint":305,"contacts":306},"Guy's Hospital","SE1 9RT",{"type":110,"coordinates":304},[291,292],{"lat":292,"lon":291},[307,311],{"name":308,"role":97,"phone":309,"phoneExt":99,"email":310},"James Spicer","020 7188 4260","james.spicer@kcl.ac.uk",{"name":312,"role":93,"phone":99,"phoneExt":99,"email":99},"James Spicer, Dr",{"facility":314,"status":104,"city":287,"state":99,"zip":315,"country":107,"countryCode":108,"cosmosGeoPoint":316,"geoPoint":318,"contacts":319},"Great Ormond Street Hospital","WC1N 3JH",{"type":110,"coordinates":317},[291,292],{"lat":292,"lon":291},[320,324],{"name":321,"role":97,"phone":322,"phoneExt":99,"email":323},"Darren Hargrave, Dr","0207 813 8525","Darren.hargrave@gosh.nhs.uk",{"name":321,"role":93,"phone":99,"phoneExt":99,"email":99},{"facility":326,"status":104,"city":327,"state":99,"zip":328,"country":107,"countryCode":108,"cosmosGeoPoint":329,"geoPoint":333,"contacts":334},"Royal Manchester Children's Hospital","Manchester","M13 9WL",{"type":110,"coordinates":330},[331,332],-2.23743,53.48095,{"lat":332,"lon":331},[335,339],{"name":336,"role":97,"phone":337,"phoneExt":99,"email":338},"Guy Makin, Dr","0161 701 8419","Guy.Makin@mft.nhs.uk",{"name":336,"role":93,"phone":99,"phoneExt":99,"email":99},{"facility":92,"status":104,"city":327,"state":99,"zip":341,"country":107,"countryCode":108,"cosmosGeoPoint":342,"geoPoint":344,"contacts":345},"M20 4BX",{"type":110,"coordinates":343},[331,332],{"lat":332,"lon":331},[346,349],{"name":91,"role":97,"phone":347,"phoneExt":99,"email":348},"0161 918 7672","matthew.krebs@nhs.net",{"name":350,"role":93,"phone":99,"phoneExt":99,"email":99},"Matthew Krebs",{"facility":352,"status":104,"city":353,"state":99,"zip":354,"country":107,"countryCode":108,"cosmosGeoPoint":355,"geoPoint":359,"contacts":360},"Clatterbridge Cancer Centre","Metropolitan Borough of Wirral","CH63 4JY",{"type":110,"coordinates":356},[357,358],-3.10501,53.37616,{"lat":358,"lon":357},[361,365],{"name":362,"role":97,"phone":363,"phoneExt":99,"email":364},"Dan Palmer, Dr","0151 706 4172 \u002F 0151 706 4177","daniel.palmer@liverpool.ac.uk",{"name":362,"role":93,"phone":99,"phoneExt":99,"email":99},{"facility":367,"status":104,"city":368,"state":99,"zip":369,"country":107,"countryCode":108,"cosmosGeoPoint":370,"geoPoint":374,"contacts":375},"Great North Children's Hospital","Newcastle","NE1 4LP",{"type":110,"coordinates":371},[372,373],-5.88979,54.21804,{"lat":373,"lon":372},[376,380],{"name":377,"role":97,"phone":378,"phoneExt":99,"email":379},"Alastair Greystoke, Dr","0191 2138476","Alastair.Greystoke@newcastle.ac.uk",{"name":377,"role":93,"phone":99,"phoneExt":99,"email":99},{"facility":382,"status":104,"city":368,"state":99,"zip":383,"country":107,"countryCode":108,"cosmosGeoPoint":384,"geoPoint":386,"contacts":387},"Freeman Hospital","NE7 7DN",{"type":110,"coordinates":385},[372,373],{"lat":373,"lon":372},[388,390],{"name":377,"role":97,"phone":378,"phoneExt":99,"email":389},"Greystoke@newcastle.ac.uk",{"name":377,"role":93,"phone":99,"phoneExt":99,"email":99},{"facility":392,"status":104,"city":393,"state":99,"zip":394,"country":107,"countryCode":108,"cosmosGeoPoint":395,"geoPoint":399,"contacts":400},"Churchill Hospital","Oxford","OX3 7LE",{"type":110,"coordinates":396},[397,398],-1.25596,51.75222,{"lat":398,"lon":397},[401,405],{"name":402,"role":97,"phone":403,"phoneExt":99,"email":404},"Sarah Pratap, Dr","01865 235273","Sarah.Pratap@ouh.nhs.uk",{"name":402,"role":93,"phone":99,"phoneExt":99,"email":99},{"facility":407,"status":104,"city":393,"state":99,"zip":408,"country":107,"countryCode":108,"cosmosGeoPoint":409,"geoPoint":411,"contacts":412},"John Radcliffe Hospital","OX3 9DU",{"type":110,"coordinates":410},[397,398],{"lat":398,"lon":397},[413,414],{"name":402,"role":97,"phone":403,"phoneExt":99,"email":404},{"name":402,"role":93,"phone":99,"phoneExt":99,"email":99},{"facility":416,"status":104,"city":417,"state":99,"zip":418,"country":107,"countryCode":108,"cosmosGeoPoint":419,"geoPoint":423,"contacts":424},"Weston Park Hospital","Sheffield","S10 2SJ",{"type":110,"coordinates":420},[421,422],-1.4659,53.38297,{"lat":422,"lon":421},[425,429],{"name":426,"role":97,"phone":427,"phoneExt":99,"email":428},"Sarah Danson, Dr","0114 226 5068","s.danson@sheffield.ac.uk",{"name":426,"role":93,"phone":99,"phoneExt":99,"email":99},{"facility":431,"status":104,"city":417,"state":99,"zip":432,"country":107,"countryCode":108,"cosmosGeoPoint":433,"geoPoint":435,"contacts":436},"Sheffield's Children's Hospital","S10 2TH",{"type":110,"coordinates":434},[421,422],{"lat":422,"lon":421},[437,441],{"name":438,"role":97,"phone":439,"phoneExt":99,"email":440},"Daniel Yeomanson, Dr","01142717366","danyeomanson@nhs.net",{"name":438,"role":93,"phone":99,"phoneExt":99,"email":99},{"facility":443,"status":104,"city":444,"state":99,"zip":445,"country":107,"countryCode":108,"cosmosGeoPoint":446,"geoPoint":450,"contacts":451},"Southampton General Hospital","Southampton","SO16 6YD",{"type":110,"coordinates":447},[448,449],-1.40428,50.90395,{"lat":449,"lon":448},[452,456],{"name":453,"role":97,"phone":454,"phoneExt":99,"email":455},"Juliet Gray, Prof","0238 120 6639","Juliet.Gray@uhs.nhs.uk",{"name":453,"role":93,"phone":99,"phoneExt":99,"email":99},{"facility":458,"status":104,"city":459,"state":99,"zip":460,"country":107,"countryCode":108,"cosmosGeoPoint":461,"geoPoint":465,"contacts":466},"The Royal Marsden Hospital","Sutton","SM2 5PT",{"type":110,"coordinates":462},[463,464],-0.2,51.35,{"lat":464,"lon":463},[467,471],{"name":468,"role":97,"phone":469,"phoneExt":99,"email":470},"Lynley Marshall, Dr","0208 661 3678","LynleyVanessa.Marshall@icr.ac.uk",{"name":468,"role":93,"phone":99,"phoneExt":99,"email":99},{"type":473,"investigatorFullName":99,"investigatorTitle":99,"investigatorAffiliation":99,"oldNameTitle":99,"oldOrganization":99},"SPONSOR",[475,477,479,481,484],{"name":476,"class":6},"University of Manchester",{"name":478,"class":6},"University of Birmingham",{"name":480,"class":6},"Royal Marsden NHS Foundation Trust",{"name":482,"class":483},"Hoffmann-La Roche","INDUSTRY",{"name":485,"class":483},"Novartis Pharmaceuticals","100494800","phase-2-determine-determining-extended-therapeutic-indications-for-existing-drugs-in-rare-molecularly-defined-indications-using-a-national-evaluation-platform-trial---master-screening-protocol-100494800",false,"NCT05722886","DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol","DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage\u002FYoung Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations","DETERMINE","THE PATIENT MUST FULFIL THE ELIGIBILITY CRITERIA OUTLINED BELOW AND WITHIN THE SPECIFIC TREATMENT ARM APPENDIX TO WHICH THEY ARE ENROLLED.\n\nCore Inclusion Criteria:\n\n1. Any patient (adult patients or children and TYA as defined in each treatment arm appendix) with histologically proven locally advanced or metastatic cancer (solid tumour or haematological malignancy) who has:\n\n   1. exhausted (or declined) standard-of-care treatment options.\n   2. or for whom no effective standard treatment is available.\n   3. and whose disease has progressed or is refractory. Exceptional circumstances may apply as described in the protocol.\n2. Diagnosis of a rare cancer harbouring an actionable genomic alteration, or common cancer types with rare actionable genomic alterations, that has been identified using a validated next-generation sequencing method and for which there is a relevant open treatment arm within the DETERMINE trial.\n3. Life expectancy of at least three months.\n4. Patients are able to provide written (signed and dated) informed consent and be capable of co-operating with treatment and follow-up. For patients under 16 years old, the parent or legal guardian will be asked to provide written informed consent and the patient will be asked to provide age-appropriate assent (written or verbal, commensurate with age and level of understanding).\n5. Patients with objectively evaluable or measurable disease, according to an assessment method appropriate for their cancer type.\n6. Patients must provide a fresh tissue biopsy at baseline and blood samples for translational research. Note that for patients with haematological malignancies or neuroblastomas, blood, bone marrow and\u002For trephine, lymph node or lump biopsy samples may be taken. For patients with haematological malignancies, a skin punch biopsy may also be taken.\n7. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (ECOG performance status 2 may be considered on an individual basis) (adults), Karnofsky score ≥50% (TYA) or Lansky Play scales ≥50% (\\\u003C12 years). Please see specific treatment arm appendices for any variations on this criterion and for definitions of adult and paediatric populations. Note: Paediatric patients: patients with Central Nervous System (CNS) tumours and a stable neurological deficit may be eligible with a performance status below 50%, at the discretion of the Investigator. In such cases, the deficit must be stable for at least 7 days prior to trial enrolment and be assessed by the local investigator as due to tumour or due to a post-surgical AE.\n8. Women of childbearing potential are eligible provided that they meet the following criteria:\n\n   * Have a negative serum or urine pregnancy test before enrolment and\n   * Agree to the birth control methods and duration of use of those methods, as specified in each treatment arm appendix.\n9. Male patients with partners of childbearing potential are eligible provided that they agree to the birth control methods and duration of use of those methods, as specified in each treatment arm appendix.\n\nCore exclusion criteria:\n\n1. Ongoing AEs Common Terminology Criteria of Adverse Events (CTCAE) Grade ≥2 attributable to previous anti-cancer treatments. Exceptions to this are any clinically stable AEs, which in the opinion of the Investigator should not exclude the patient.\n2. At high medical risk, in the opinion of the Investigator, because of non-malignant systemic disease (including active uncontrolled infection).\n3. Female patients who are pregnant, breastfeeding or planning to become pregnant or male patients with a partner who is a woman of childbearing potential and is planning to become pregnant during the trial or following the last dose of IMP, as specified in each treatment arm appendix.\n4. Is (or plans to be) a patient in another interventional clinical trial, whilst taking part in this trial. Participation in an observational trial which does not involve administration of an Investigational Medicinal Product (IMP) and which, in the opinion of the local Investigator, would not place an unacceptable burden on the patient would be acceptable e.g. sample collection\\* or QoL studies.\n\n   \\*for paediatric patients participating in other studies involving tissue\u002Fcirculating tumour (ct) DNA\u002Fother blood collection, consideration would need to be given to the total blood volumes collected (as per the European Medicines Agency blood volume limits for children).\n5. Co-administration of anti-cancer therapies other than those administered in this trial (with the exception of lifelong hormone suppression such as luteinising hormone agonists\u002Fanalogues in prostate cancer).\n6. Radiotherapy (except for palliative reasons) or chemotherapy, endocrine therapy (except when given for conditions other than malignant disease; e.g. thyroid replacement for hypothyroidism, hydrocortisone for cortisol deficiency\u002Fpanhypopituitarism), nitrosoureas, mitomycin-C, immunotherapy and molecularly targeted agents or other IMPs within 4 weeks or 5 half-lives (whichever is the shorter).\n7. Rapidly progressing or symptomatically deteriorating brain metastases. Patients with previously treated brain metastases are eligible, provided the patient has not experienced a seizure or had a clinically significant change in neurological status within the 14 days (for adult patients) or 7 days (for paediatric patients) prior to the start of IMP administration. Such patients must be non-dependent on steroids or on a stable or reducing dose of steroid treatment for at least 14 days (or 7 days for paediatric patients) prior to the start of IMP administration. Primary brain or CNS malignancies are allowed providing the patient is clinically stable (if requiring corticosteroids must be at stable or decreasing doses for at least 14 days for adults and 7 days for paediatric patients prior to the start of IMP administration). Patients who have received brain irradiation must have completed whole-brain radiotherapy and\u002For stereotactic radiosurgery at least 14 days prior to the start of IMP administration.\n8. Any other condition which, in the opinion of the local Investigator, would not be in the best interests of the patient.","ALL",{"count":496,"type":497},825,"ESTIMATED","INTERVENTIONAL",[500,501],"PHASE2","PHASE3","DETERMINE is an open-label phase II\u002FIII trial. It will look at targeted treatments in rare cancers or common cancers with rare genetic change (mutation). Patients must have a cancer with an identified mutation. This could be found during routine testing or as part of another research programme. The DETERMINE trial will recruit adults, teenagers and children. If a drug is found to benefit a new patient group, the study team will work with the NHS and the Cancer Drugs Funds to see if these drugs can be available for patients in the future. This clinicaltrials.gov record refers to the Overall Trial Protocol (Master Screening Record), additional records will be added to clinicaltrials.gov for each treatment arm.",[504,505],"Haematological Malignancy","Solid Tumour",[507,47,508,509,53,510,511,512,513,514,59,515,516,517,518,519,520,521,522,523,524,525,526,527,528,529,530,531,532,533,534,535,536,77,537,538,539],"Adult","ALK Tyrosine Kinase Receptor","Antineoplastic Agents","BRAF Kinase","Cancer","Child","CMMRD","Cobimetinib","Genes, HER2","Immune Checkpoint Inhibitors","Immunological","Lymphoproliferative Disorders","Malignancy","Malignant Neoplasms","MSI","Molecular Targeted Therapy","Mutation","Neoplasms by Histologic Type","Neoplasms by Site","Paediatric","Pertuzumab","Precision Medicine","Protein Kinase Inhibitors","Rare","ROS1 protein, human","TMB","Trastuzumab","Tumour-agnostic","Vemurafenib","Young adult","MET","Dabrafenib","Trametinib","2026-06-29",{"date":542,"type":543},"2026-07-01","ACTUAL",{"date":545,"type":543},"2023-03-01",{"date":547,"type":497},"2029-10",{"name":5,"class":6},27]